{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T21:26:07Z","timestamp":1655846767887},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2012,9,5]],"date-time":"2012-09-05T00:00:00Z","timestamp":1346803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s10067-012-2081-6","type":"journal-article","created":{"date-parts":[[2012,9,4]],"date-time":"2012-09-04T06:50:12Z","timestamp":1346741412000},"page":"1707-1711","source":"Crossref","is-referenced-by-count":11,"title":["Adherence to uric acid treatment guidelines in a rheumatology clinic"],"prefix":"10.1007","volume":"31","author":[{"given":"Richard","family":"Conway","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Coughlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,5]]},"reference":[{"key":"2081_CR1","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK (2011) Prevalence of gout and hyperuricemia in the US general population. Arthritis Rheum 63:3136\u20133141","journal-title":"Arthritis Rheum"},{"key":"2081_CR2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.071229","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J, Edwards L, Kawata AK, Frank L, Waltrip R, Maroli A, Huang B, Gout Natural History Study Group, Sundy JS (2009) Quality of life and disability in patients with treatment-failure gout. J Rheumatol 36:1041\u20131048","journal-title":"J Rheumatol"},{"key":"2081_CR3","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1136\/ard.2010.128454","volume":"69","author":"N Schlesinger","year":"2010","unstructured":"Schlesinger N, Thiele RG (2010) The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 69:1907\u20131912","journal-title":"Ann Rheum Dis"},{"key":"2081_CR4","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liot\u00e9 F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Piment\u00e3o J, Punzi L, Roddy E, Uhlig T, Zimmermann-G\u00f2rska I, EULAR Standing Committee for International Clinical Studies Including Therapeutics (2006) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1312\u20131324","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"2081_CR5","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1093\/rheumatology\/kep086","volume":"48","author":"M Doherty","year":"2009","unstructured":"Doherty M (2009) New insights into the epidemiology of gout. Rheumatology (Oxford) 48(Suppl 2):ii2\u2013ii8","journal-title":"Rheumatology (Oxford)"},{"key":"2081_CR6","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"KM Jordan","year":"2007","unstructured":"Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, Hingorani A, Jaques R, Nuki G, British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG) (2007) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 46:1372\u20131374","journal-title":"Rheumatology (Oxford)"},{"key":"2081_CR7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/intqhc\/mzr036","volume":"23","author":"SW Oh","year":"2011","unstructured":"Oh SW, Lee HJ, Chin HJ, Hwang JI (2011) Adherence to clinical practice guidelines and outcomes in diabetic patients. Int J Qual Health Care 23:413\u2013419","journal-title":"Int J Qual Health Care"},{"key":"2081_CR8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/intqhc\/mzq051","volume":"22","author":"DJ Ballard","year":"2010","unstructured":"Ballard DJ, Ogola G, Fleming NS, Stauffer BD, Leonard BM, Khetan R, Yancy CW (2010) Impact of a standardized heart failure order set on mortality, readmission, and quality and costs of care. Int J Qual Health Care 22:437\u2013444","journal-title":"Int J Qual Health Care"},{"issue":"50","key":"2081_CR9","first-page":"496","volume":"2010","author":"MB Nichol","year":"2003","unstructured":"Nichol MB, Knight TK, Priest JL, Wu J, Cantrell CR (2003) Nonadherence to clinical practice guidelines and medications for multiple chronic conditions in a California Medicaid population. J Am Pharm Assoc 2010(50):496\u2013507","journal-title":"J Am Pharm Assoc"},{"key":"2081_CR10","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1056\/NEJMsa022615","volume":"348","author":"EA McGlynn","year":"2003","unstructured":"McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, Kerr EA (2003) The quality of health care delivered to adults in the United States. N Engl J Med 348:2635\u20132645","journal-title":"N Engl J Med"},{"key":"2081_CR11","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","volume":"81","author":"CA Sarawate","year":"2006","unstructured":"Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW (2006) Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 81:925\u2013934","journal-title":"Mayo Clin Proc"},{"key":"2081_CR12","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/keh679","volume":"44","author":"TR Mikuls","year":"2005","unstructured":"Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG (2005) Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 44:1038\u20131042","journal-title":"Rheumatology (Oxford)"},{"key":"2081_CR13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00296-009-1056-7","volume":"30","author":"GC Wall","year":"2010","unstructured":"Wall GC, Koenigsfeld CF, Hegge KA, Bottenberg MM (2010) Adherence to treatment guidelines in two primary care populations with gout. Rheumatol Int 30:749\u2013753","journal-title":"Rheumatol Int"},{"key":"2081_CR14","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/ard.2007.070755","volume":"66","author":"E Roddy","year":"2007","unstructured":"Roddy E, Zhang W, Doherty M (2007) Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 66:1311\u20131315","journal-title":"Ann Rheum Dis"},{"key":"2081_CR15","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"SL Wallace","year":"1977","unstructured":"Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Y\u00fc TF (1977) Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20:895\u2013900","journal-title":"Arthritis Rheum"},{"key":"2081_CR16","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(01)06411-X","volume":"358","author":"JA Staessen","year":"2001","unstructured":"Staessen JA, Wang JG, Thijs L (2001) Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358:1305\u20131315","journal-title":"Lancet"},{"key":"2081_CR17","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","unstructured":"The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977\u2013986","journal-title":"N Engl J Med"},{"key":"2081_CR18","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837\u2013853","journal-title":"Lancet"},{"key":"2081_CR19","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/ard.2009.123976","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Knevel R, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas DT, Burmester G, Combe B, Cutolo M, Dougados M, Emery P, van der Heijde D, Huizinga TW, Kalden J, Keystone EC, Kvien TK, Martin-Mola E, Montecucco C, de Wit M, Smolen JS (2010) Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 69:638\u2013643","journal-title":"Ann Rheum Dis"},{"key":"2081_CR20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"AM Gestel van","year":"1996","unstructured":"van Gestel AM, Prevoo ML, van\u2019t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League against Rheumatism Criteria. Arthritis Rheum 39:34\u201340","journal-title":"Arthritis Rheum"},{"key":"2081_CR21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","volume":"63","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landew\u00e9 R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M, American College of Rheumatology; European League Against Rheumatism (2011) American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63:573\u2013586","journal-title":"Arthritis Rheum"},{"key":"2081_CR22","first-page":"2016","volume":"32","author":"GA Wells","year":"2005","unstructured":"Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, Aletaha D, Anderson JJ, Bombardier C, Dougados M, Emery P, Felson DT, Fransen J, Furst DE, Hazes JM, Johnson KR, Kirwan JR, Landew\u00e9 RB, Lassere MN, Michaud K, Suarez-Almazor M, Silman AJ, Smolen JS, Van der Heijde DM, van Riel PL, Wolfe F, Tugwell PS (2005) Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 32:2016\u20132024","journal-title":"J Rheumatol"},{"key":"2081_CR23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van\u2019t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44\u201348","journal-title":"Arthritis Rheum"},{"key":"2081_CR24","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C (2009) Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 36:1273\u20131282","journal-title":"J Rheumatol"},{"key":"2081_CR25","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353:2450\u20132461","journal-title":"N Engl J Med"},{"key":"2081_CR26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","volume":"57","author":"F Perez-Ruiz","year":"1998","unstructured":"Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garc\u00eda-Erauskin G, Ruiz-Lucea E (1998) Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 57:545\u2013549","journal-title":"Ann Rheum Dis"},{"key":"2081_CR27","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12:R63","journal-title":"Arthritis Res Ther."},{"key":"2081_CR28","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59:1540\u20131548","journal-title":"Arthritis Rheum."},{"key":"2081_CR29","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, Brouwers JR (2009) A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300\u2013600 mg\/day versus benzbromarone 100\u2013200 mg\/day in patients with gout. Ann Rheum Dis 68:892\u2013897","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-012-2081-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-012-2081-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-012-2081-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:57:22Z","timestamp":1559105842000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-012-2081-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,5]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["2081"],"URL":"https:\/\/doi.org\/10.1007\/s10067-012-2081-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,5]]}}}